GHWP/WG2-WG1-WG3/PD001:2021



Asian Harmonization Working Party working towards medical device harmonization in asia

PROPOSED DOCUMENT

Title:	Regulatory mechanism for Medical Devices including In Vitro Diagnostic Medical Devices and Software as Medical Devices during a public health emergency
Authoring Group:	Work Group 1, Pre-Market Submission and CSDT Work Group 2, Pre-market: IVDD
	Work Group 3, Pre-market: Software as a Medical Device
Date:	November 2021

Dr. Seil Park Chair, Work Group 1

Dr. Wen-Wei Tsai Chair, Work Group 2 Mr. Abdullatif Al Watban *Chair, Work Group 3*

Copyright © 2021 by the Global Harmonization Working Party All Rights Reserved

Acknowledgements This Guidance document was led by Work Group 2 and with subsequent contributions from Technical Committee: Mr. Alfred KWEK; Work Group 2: Dr. Adelheid SCHNEIDER, Dr. Jane SC TSAI, Ms. Jacqueline C. MONTEIRO, Ms. Razan ASALLY, Ms. Shelley TANG, Ms. Yin-ting FANN; Work Group 1: Ms. Mandy Myoung Shim KIM; Work Group 3: Mr. Tony YIP, Mr. Pavan Kumar MALWADE, Ms. Marwa AL SHEHEIMI, Ms. Zahra AL-HOOTI, Mr. Varun VEIGAS, Dr. Ir Peter W. J. LINDERS and Ms. Irena PRAT, Mr. Charles CHIKU of WHO, whom we would like to greatly acknowledge.

34 **Preface**

35 The Global Harmonization Working Party established this document based on Emergency use and

36 specific COVID 19 guidelines worldwide. The document is intended to provide non-binding

37 guidance for use in the regulatory system of medical devices, including in vitro diagnostic (IVD)

38 medical devices and software as a medical device (SaMD), and has been subject to consultation

39 throughout its development.

40 There are no restrictions on the reproduction, distribution, translation or use of this document.

41 However, incorporation of this document, in part or in whole, into any other document does not

42 convey or represent an endorsement of any kind by the Global Harmonization Working Party.

45 46 47 1.0 Introduction	
471.0Introduction482.0Rationale, Purpose and Scope492.1Rationale502.2Purpose512.3Scope523.0References534.0Terminology and Definitions545.0General Principles555.1Good Reliance Practice565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	
482.0Rationale, Purpose and Scope	
492.1Rationale	
502.2Purpose512.3Scope523.0References534.0Terminology and Definitions545.0General Principles555.1Good Reliance Practice565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	6 6
512.3Scope523.0References534.0Terminology and Definitions545.0General Principles555.1Good Reliance Practice565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	6
523.0References	
534.0Terminology and Definitions545.0General Principles555.1Good Reliance Practice565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility61Eligibility626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	
545.0General Principles555.1Good Reliance Practice565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	11 11 12
555.1Good Reliance Practice565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	11 12
565.1.1Recognition575.1.2Reliance585.2Risk-calibrated & phased approach596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	12
575.1.2 Reliance	
585.2Risk-calibrated & phased approach	13
596.Emergency Regulatory Mechanism606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	
606.1Eligibility616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	
616.2Procedures626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	
626.2.1Expert group636.2.2Pre-EUA submission meeting646.2.3EUA Submission656.2.4Review/Audit/Inspection666.2.5Emergency Authorization676.2.6Post authorization monitoring686.2.7Changes	15
 63 6.2.2 Pre-EUA submission meeting 64 6.2.3 EUA Submission 65 6.2.4 Review/Audit/Inspection	
646.2.3 EUA Submission.656.2.4 Review/Audit/Inspection666.2.5 Emergency Authorization	
656.2.4 Review/Audit/Inspection666.2.5 Emergency Authorization676.2.6 Post authorization monitoring686.2.7 Changes	
 66 6.2.5 Emergency Authorization	
676.2.6Post authorization monitoring686.2.7Changes	
68 6.2.7 Changes	
8	
69 6.2.8 Duration	
70 6.2.9 Conversion	
71 Annex: Essential requirements for emergency regulatory authorization of Medical De	
72 A. Table of Content for Dossier for Medical Devices	
73 B. Table of Content for Dossier for IVD Medical Devices	
74 C. Table of Content for Dossier for Software as Medical Device	
75 D. Quality Management System Documents	
76 E. Clinical Evidence Requirements – Medical Devices and Software as Medica	al Devices
77 25	26
78 F. Clinical Evidence Requirements – IVD Medical Devices	
79 G. Labelling	
80	
81	
82	

84 **1.0 Introduction**

The objective of the Global Harmonization Working Party (GHWP) is to encourage convergence at the worldwide level in the evolution of regulatory systems of medical devices, including in vitro diagnostic (IVD) medical devices and software as a medical device (SaMD), in order to protect the public health by those regulatory means considered the most suitable.

89 It is widely recognized that public health emergencies (i.e. COVID-19, SARS, Ebola, MERS, Zika, 90 etc.), whether they rise to the level of global pandemics or not, could have immense impact on all 91 aspects of people's lives and wellbeing, and on economic development and social prosperity. They

92 often strain the entire healthcare system, including regulatory authorities, which play an

- 92 often strain the entire heatincare system, including regulatory authorities, which play an
 93 instrumental role in tackling the public health emergency by enabling timely and adequate access
 94 to essential medical products.
- 95
- GHWP acknowledges the existence and/or recognition of some jurisdictions' (national or regional)
 guidance's on emergency regulatory mechanisms. However no global guidance on emergency
 regulatory mechanisms yet exists. Such a guidance could be referenced and adopted by regulatory
 authorities worldwide without regard to their size or resources, and would be a critical component
- 100 of national emergency preparedness.
- 101

This guidance serves as GHWP's general recommendations and procedures applicable to an
 emergency regulatory mechanism for certain Medical Devices including in vitro diagnostic
 (IVD) medical devices and software as a medical device (SaMD).

105

This guidance document has been developed to ensure that **essential medical devices** for diagnosis, treatment, mitigation and/or prevention of a public health emergency, could be adequately accessed in a fast and sustainable manner. This guidance was developed with a risk-based and agile mindset, taking into consideration the evolving medical knowledge around the possibly new pathogen and its mutations, the frequently iterative innovation of products, as well as the unique supply and logistics challenges during public health emergencies.

112

GHWP believes this guidance will sustain and strengthen national preparedness for public healthemergency situations.

- 115 Work Group 2 of the GHWP has prepared this guidance document. Comments or questions should
- 116 be directed to the Chair of GHWP Work Group 2 whose contact details may be found on the
- 117 GHWP web page (<u>http://www.ahwp.info/</u>).
- 118
- 119

120 **2.0 Rationale, Purpose and Scope**

121 **2.1 Rationale**

Regulatory authorities around the world have to respond rapidly in a public health crisis.
Governments typically are under extraordinary time pressure to swiftly develop policy responses
to address such public health emergencies to contain the severity and spread.

125

126 As Medical Devices including in vitro diagnostic (IVD) medical devices and software as a medical 127 device (SaMD) play an instrumental role in managing a public health emergency, guidelines and

- 128 policies to facilitate accelerated availability of Medical Devices are much needed.
- 129

130 GHWP has developed this guidance to assist interested Member Economies in setting up or modifying

- 131 the regulatory emergency mechanism to better meet the urgent demands of essential medical devices
- 132 including in vitro diagnostic (IVD) medical devices and software as a medical device (SaMD) in
- 133 the context of a public health emergency.

134 **2.2 Purpose**

135 The purpose of this document is to define general regulatory principles as well as specific

- 136 procedures and minimum requirements in granting adequate access and ensuring the safety and
- 137 performance and/or effectiveness of Medical Devices, IVD Medical Devices and SaMD during
- 138 public health emergencies.

139 **2.3** Scope

This guideline addresses the emergency regulatory mechanism for Medical Devices including in
vitro diagnostic (IVD) medical devices and software as a medical device (SaMD), as defined in
the AHWP/WG2-WG1/F001:2016 Definition of the Terms 'Medical Device' and 'In Vitro
Diagnostic (IVD) Medical Device' guideline and the AHWP/WG3/F001:2015 Guidance
Document on Medical Device Software - Qualification and Classification respectively.

145

146 **3.0 References**

- 147 AHWP/WG2-WG1/F001:2016 Definition of the Terms 'Medical Device' and 'In Vitro
- 148 Diagnostic (IVD) Medical Device'
- 149 AHWP/WG1a/F002:2013 (now restructured to WG2) Essential Principles of Safety and
- 150 Performance/effective of IVD Medical Devices
- AHWP/WG3/F001:2016 Guidance document on Risk Categorisation of Software as a Medical
 Device
- AHWP/WG3/F001:2015 Guidance Document on Medical Device Software Qualification and
 Classification
- 155 AHWP/WG5/F003:2015 Clinical Evidence for IVD Medical Device Key Definitions and
- 156 Concepts
- 157 AHWP/WG5/F004:2015 Clinical Evidence for IVD Scientific Validity Determination and

- 158 *Performance Evaluation*
- 159 AHWP "Guidance on Clinical Evidence for IVD Medical Devices Clinical Performance
- 160 Studies for In Vitro Diagnostic Medical Devices"
- 161 AHWP/WG1-WG2/F001:2017 Regulation and treatment of e-IFU and e-Label of Medical
- 162 Devices-Review of International Practice
- 163 AHWP/WG1-WG2-WG3/F002:2019 Principles of Regulatory Requirements for Electronic
- 164 Instructions for Use (eIFU)
- 165 AHWP/WG2/F001:2018 Labelling for In Vitro Diagnostic Medical Devices
- 166 AHWP/WG2-WG1-WG3/F001:2019- Categorisation of Changes to a registered Medical Device
- 167 AHWP/WG1/F002:2016 Guidance for Minor Change Reporting
- 168 AHWP/WG4/F001:2015 Adverse Event Reporting Guidance for the Medical Device
- 169 Manufacturer or its Authorized Representative
- 170 AHWP/WG4/F001:2014 Adverse Event Reporting Timelines Guidance for Medical Device
- 171 Manufacturer and its Authorised Representative
- 172 US Emergency Use Authorization of Medical Products and Related Authorities
- 173 US Immediately in Effect Guidance on policy for diagnostics testing in laboratories certified to
- perform high complexity testing under CLIA prior to Emergency Use Authorization forCoronavirus Disease-2019 during the public health emergency
- US Guidance for Industry and Food and Drug Administration Staff "Use of Real-World
 Evidence to Support Regulatory Decision-Making for Medical Devices"
- Evidence to Support Regulatory Decision-Making for Medical Devices
- US Draft Guidance for Industry, Food and Drug Administration Staff, and Clinical
 Laboratories Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)
- 180 US Guidance for Industry, Food and Drug Administration Staff, and Clinical Laboratories
- 181 Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational
- 182 Use Only
- 183 Canada Interim order respecting the importation and sale of medical devices for use in relation184 to COVID-19
- 185 Kingdom of Saudi Arabia Corona Virus (Covid-19) IVD Tests Emergency Use Authorization
 186 (EUA)
- 187 Singapore Guidance on expedited approval of COVID-19 Diagnostic Tests Provisional
 188 Authorisation
- 189 China Emergency Approval Procedures
- Australia Therapeutic Goods (Medical Devices Face Masks and Other Articles) (COVID-19
 Emergency) Exemption 2020
- Korea Guideline on the review and approval of In vitro Diagnostics Device for COVID-19 (forIndustry)
- 194 Taiwan Special Approvals: Nucleic Acid Tests for SARS-CoV-2
- 195 Taiwan Special Approvals: Rapid Screening Antibody Tests for SARS-CoV-2

- 196 Taiwan Special Approvals: Rapid Screening Antigen Tests for SARS-CoV-2
- 197 Taiwan Special Approvals: Ventilator for Patients with Respiratory Failure or Respiratory
- 198 Insufficiency
- 199 WHO Emergency Use Listing Procedure
- 200 WHO Instructions and requirements for Emergency Use Listing (EUL) Submission: In vitro
- 201 diagnostics detecting SARS-CoV-2 nucleic acid or antigen
- WHO Instructions and requirements for Emergency Use Listing (EUL) Submission: In vitro
 diagnostics detecting antibodies to SARS-CoV- 2 virus
- WHO Good reliance practices in regulatory decision-making: high-level principles andrecommendations
- ISO 13485 Medical devices Quality management systems— Requirements for regulatory
 purposes
- 208 ISO 14971 Medical devices Application of risk management to medical devices
- 209 ISO 20916:2019 In vitro diagnostic medical devices Clinical performance studies using
- 210 specimens from human subjects Good study practice
- ISO 14155:2011 Clinical investigation of medical devices for human subjects Good clinical
 practice
- 213

214 **4.0 Terminology and Definitions**

- 215 **Emergency Use Authorization (EUA)** Mechanism established by Regulatory Authority to
- 216 facilitate the availability and use of medical devices during public health emergencies, such as 217 the current COVID-19 pandemic.
- 218 Note-Under an EUA, the Regulatory Authority may allow the use of otherwise unapproved
- 219 products, or unapproved uses of approved products in an emergency to diagnose, treat, or
- 220 prevent serious or life-threatening diseases or conditions when certain criteria have been met,
- 221 *including that there are no adequate, approved, and available alternatives.*
- Medical Device The term is as defined in AHWP/WG2-WG1/F001:2016 Definition of the
 Terms 'Medical Device' and 'In Vitro Diagnostic (IVD) Medical Device'
- **IVD Medical Device -** The term is as defined in AHWP/WG2-WG1/F001:2016 Definition of
 the Terms 'Medical Device' and 'In Vitro Diagnostic (IVD) Medical Device'
- Software as a Medical Device (SaMD) The term is as defined in IMDRF/SaMD
 WG/N10FINAL:2013 Software as a Medical Device (SaMD): Key Definitions
- 228 **Manufacturer -** For the purpose of this document, the term "manufacturer" includes the
- 229 manufacturer, its authorized representative or any other person who is responsible for placing the 230 device on the market.
- **Regulatory Authority-** It is a government agency or other entity that exercises a legal right to control the use or sale of medical devices within its jurisdiction, and may take enforcement action to ensure that medical products marketed within its jurisdiction comply with legal requirements.
- 234 (AHWP/WG1a-WG7/PD007)

- Risk Management It is a systematic application of management policies, procedures and
 practices to the tasks of analyzing, evaluating, controlling and monitoring risk (e.g., ISO
 14971:2007 Medical devices Application of risk management to medical devices)
- 238 **Recognition** The acceptance of the regulatory decision of another regulator or other trusted
- 239 institution. Recognition should be based on evidence of conformity that the regulatory
- 240 requirements of the reference health authority is sufficient to meet the regulatory requirements of
- the relying authority. Recognition may be unilateral or mutual and may, in the latter case, be the
- subject of a mutual recognition agreement. (WHO definition Good reliance practices in
- 243 regulatory decision-making: high-level principles and recommendations)
- Reference health authority National or regional authority being relied upon by another health
 authority. (WHO definition Good reliance practices in regulatory decision-making: high-level
 principles and recommendations)
- 247 **Reliance -** The act whereby the NRA in one jurisdiction may take into account and give
- 248 significant weight to assessments performed by another NRA or trusted institution, or to any
- 249 other authoritative information in reaching its own decision. The relying authority remains
- 250 independent, responsible and accountable regarding the decisions taken, even when it relies on
- the decisions and information of others. (WHO definition Good reliance practices in regulatory
- 252 decision-making: high-level principles and recommendations)
- Clinical Data -Safety, clinical performance and/or effectiveness information that is generated
 from the clinical use of a medical device (IMDRF MDCE WG/N56FINAL:2019 Clinical
 Evaluation)
- Clinical Evaluation A set of ongoing activities that use scientifically sound methods for the
 assessment and analysis of clinical data to verify the safety, clinical performance and/or
 effectiveness of the device when used as intended by the manufacturer (IMDRF MDCE
 WC (N5(ED) AL (2010), Clinical Evaluation)
- 259 WG/N56FINAL:2019 Clinical Evaluation)
- Clinical Evidence The clinical data and its evaluation pertaining to a medical device (IMDRF
 MDCE WG/N56FINAL:2019 Clinical Evaluation)
- Real World Evidence (RWE) It is defined by US FDA as "clinical evidence regarding the
 usage and potential benefits or risks of a medical product derived from analysis of RWD"RWE
 can be generated by different study designs or analyses, including but not limited to, randomized
 trials, including large simple trials, pragmatic trials, and observational studies (prospective
 and/or retrospective). (US Guidance for Industry and Food and Drug Administration Staff: Use
 of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices)
- Real-World Data (RWD) It is defined by US FDA as are data relating to patient health status
 and/or the delivery of health care routinely collected from a variety of sources. Examples of
 RWD include data derived from electronic health records (EHRs), claims and billing data, data
 from product and disease registries, patient-generated data including in home-use settings, and
 data gathered from other sources that can inform on health status, such as mobile devices (US -

Guidance for Industry and Food and Drug Administration Staff: Use of Real-World Evidence to
 Support Regulatory Decision-Making for Medical Devices

Laboratory Developed Test (LDT) - Diagnostic tests developed by a single clinical laboratory
 for use only in that laboratory (US Draft Guidance for Industry, Food and Drug Administration
 Staff, and Clinical Laboratories Framework for Regulatory Oversight of Laboratory Developed
 Tests (LDTs)

279 Research Use Only (RUO) - Products that are in the laboratory research phase of development, 280 that is, either basic research or the initial search for potential clinical utility, and not represented 281 as an effective in vitro diagnostic product. During this phase, the focus of manufacturer-initiated

studies is typically to evaluate limited-scale performance and potential clinical or informational

283 usefulness of the test US Guidance for Industry, Food and Drug Administration Staff, and

- 284 *Clinical Laboratories* Distribution of In Vitro Diagnostic Products Labeled for Research Use
- 285 Only or Investigational Use Only
- 286 Instructions for Use Refers to general and technical information provided by the manufacturer
- to inform the device user of the medical device or IVD medical device's intended purpose and

proper use and of any contraindications, warnings, or precautions to be taken. It is provided by


the manufacturer to support and assist the device users in its safe and appropriate use.

- 290 (AHWP/WG2/F001:2018 Labelling for In Vitro Diagnostic Medical Devices)
- Note 1: Instructions for use (IFU) can also be referred to as "package insert" or "directions for use" and may also include "User Manual" or "Technical Manual."
- Self-testing IVD Medical Device An IVD medical device intended for use by a lay user who is responsible for collecting the data or specimen, by themselves and on themselves, relying solely on the instructions provided by the manufacturer. This use can also include performing the test and interpreting the results by themselves and on themselves. (Modified from IMDRF/GRRP WC (N47EINAL 2018)
- 297 WG/N47FINAL:2018)
- Near-Patient Testing -Testing that is performed near a patient and outside of centralized laboratory
 testing facilities.
- 300 NOTE 1: Users of near-patient testing can include lay or professional users.
- 301 NOTE 2: This is not intended to refer to sample collection procedures. NOTE 3: In certain regulatory
- 302 jurisdictions, this is also referred to as Point of Care Testing.
- 303 (IMDRF/GRRP WG/N47 FINAL:2018 Essential Principles of Safety and Performance of Medical
- 304 Devices and IVD Medical Devices)
- 305 Lay person Individual that does not have formal training in a relevant field or discipline.
- 306 [SOURCE: ISO 18113-1:2009]
- 307 Note: Includes the directions supplied by the manufacturer for the use, maintenance,
- 308 troubleshooting and disposal of an IVD medical device, as well as warnings and precautions

309 **5.0** General Principles

310 Respective authorities are recommended to consider the following general principles for the set-

- 311 up or modification of emergency regulatory mechanism.
- 312
- 313



- 314 315
- 316

317 5.1 Good Reliance Practice

318

Regulatory authorities should leverage regulatory reliance models, particularly during a publichealth emergency.

321

The World Health Organization recently published *Good reliance practices in the regulation of medical products: high level principles and considerations.* This document illustrates (as shown in Fig. 1 below) the key concepts of reliance, with a broad spectrum of models, ranging from worksharing to mutual recognition.


As described by WHO, good reliance practices are beneficial for regulatory authorities, not only
during public health emergencies, but at all times. They enable regulatory authorities to make the
best use of available resources and expertise, while facilitating timely access to safe, effective,
quality-assured medical products.

330 331

Notably it has been highlighted in the WHO guidance that good reliance practices can also
 "support regulatory preparedness and response, particularly during public health

- 334 emergencies."
- 335
- 336
- 337
- 338 339
- 340
- 341
- 342
- 343

344
345
346
347
348
349
350
Figure 1 Key Concepts of Reliance (reference: WHO guidance)
351



352

353

354 **5.1.1 Recognition**

To enable Regulatory Authorities to manage a pandemic as well as performing their core functionality, leveraging recognition of reference health authorities authorizations (**including the WHO Emergency Use Listing**) is highly recommended.

358

The manufacturer shall provide proof of the authorization granted by a Reference Health Authority or the WHO EUL program for the same product. This evidence should include a copy of the formal approval letter issued by the authority, as well as any review summaries authored by the authority. For absolute certainty, if a Regulatory Authority deems that the evidence of approval by a Reference Health Authority is insufficient, the Regulatory Authority may request additional information.

Note - If a Reference Health Authority chooses to exempt a device, without evaluating in whole or in part, that recognition is not appropriate. Additionally if a foreign jurisdiction waives all (not just partial) pre-market submission and evaluation requirements, this would not be considered a reference authorization for the purposes of granting the emergency use authorization through the recognition pathway.

371 **5.1.2 Reliance**

For regulators whose legislative or regulatory frameworks do not allow complete recognition of
a Reference Health Authority's authorizations, other reliance models would be recommended to
be taken into consideration in managing a public health emergency. Reliance strategies should
be tailored to the framework and needs of the national health and regulatory systems.
WHO defines reliance as the act whereby the Health authority in one jurisdiction take into account

WHO defines reliance as the act whereby the Health authority in one jurisdiction take into account
and give significant weight to assessments performed by another Health authority or trusted
institution, or to any other authoritative information in reaching its own decision. The relying
authority remains independent, responsible and accountable regarding the decisions taken, even
when it relies on the decisions and information of others.

381

GHWP recommends the following principles, which were highlighted by the WHO guidance for
 implementing regulatory reliance frameworks or strategies:

384 385

390

391

- Universality Levels of maturity or resources are not drivers of reliance
- Sovereignty of decision-making Reliance implementation requires the existence of competencies for critical decision-making
- Transparency is key to new, more efficient ways of conducting regulatory operations,
 both locally and internationally
 - **Respect of national and regional legal basis -** Reliance should be rooted in the national legal framework in alignment with national and regional legal basis
- Consistency Reliance should focus on specific and well-defined categories of products
 and processes
- Competence The decision to practice reliance, and how best to implement reliance,
 rests with the country and does not imply dependence, loss of sovereignty and
 accountability
- 397

Additionally, reliance pathways should be considered for all relevant regulatory functions across
 the medical device product life cycle, as appropriate, such as pre-market evaluation, QMS
 including audits, post market control, etc.

401

402 5.2 Risk-calibrated & phased approach

403

404 As a public health emergency could evolve along different phases of pandemic/endemic 405 progression (as illustrated in Figure 2), it is critical for regulatory authorities to adopt a risk-406 calibrated and agile approach to cater for different needs along the disease progression.

407


It is notable that during the same global pandemic or endemic, the outbreak could progress in a
manner to go back and forth between phases as knowledge evolves and mutations occur and
could last for a relatively long time period.

- 411
- 412 Due to the different needs during the different outbreak phases, some special and fit-for-purpose
- 413 considerations could be put in place by the respective authority as appropriate.
- 414
- 415

- 416
- 417
- 418
- 419
- 420
- 421
- 422

423 **Figure 2:** Five different phases in a pandemic/endemic progression (Reference: Mckinsey

- 424 model/APACMed paper)
- 425



426

427 **Phase 1**: In the case of outbreak due to a new pathogen, close collaboration and communication

428 between Regulatory Authorities, developers, health care systems, manufacturers and citizens is

429 encouraged to get medical devices available in the market. Regulatory Authorities might accept

- unapproved medical devices or unapproved uses of approved products (including research use only
 products (RUOs) and laboratory-developed tests (LDTs)) if no appropriate medical device is
- 432 available in the market.

In this phase, Regulatory Authorities are also encouraged to consider products recommended byWHO (e.g. use the WHO recommended reagents and testing protocols).

435

Phase 2: In the phase of uncontrolled acceleration, Regulatory Authorities should prioritize access
to essential medical products that are critical for managing the outbreak. Regulatory Authorities
might still accept unapproved medical devices or unapproved uses of approved products.
Depending on the supply of the products the Regulatory Authorities might consider to tighten the

440 requirements.

441 It is highly recommended to recognize the WHO Emergency Use Listing (EUL), and emergency

- 442 authorizations by other regulatory authorities.
- 443

444 Phase 3: In the phase of deceleration, Regulatory Authorities are encouraged to leverage other 445 reliance models or its own emergency pathways with clear procedural and risk-calibrated 446 requirements and to ask minimum requirements based on the marketed product. Regulatory

- Authorities are also encouraged to leverage various regulatory collaboration platforms (such as
 WHO, IMDRF, AMDC, GHWP, APEC- RHSC, etc.) to share scientific knowledge and best
 practices for a synchronized and efficient decision-making process.
- 450

Phase 4: In the phase of control and battling resurgence, Regulatory Authorities are recommended to still prioritize resources and open fast track for the essential products, taking into consideration of risks of resurgence RA might consider transiting out of EUA and requiring products to be registered under the normal pathway (considering fast track). It is also recommended to apply the fast track for not just pre-market authorization, but also to the post market submission (rolling submission) as well as change submission.

- 457
- 458

In the **post emergency phase**, it is recommended that emergency regulatory authorizations are
allowed to be supplemented with additional evidence (real world evidence should be leveraged)
and to be converted into normal license via an efficient route.

462 If the regulatory system of the country allows a completely new submission for the same product 463 via the normal route, the conversion should not be requested.

464

465 6. Emergency Regulatory Mechanism

The purpose of setting up emergency regulatory mechanism is to allow the use of unapproved medical devices, or unapproved uses of approved medical devices in a public health emergency crisis, where some minimal criteria have to be met.

469

The key concept for emergency regulatory mechanism is making risk-calibrated regulatory decision, weighting the potential benefits against the potential risks caused by the public health emergency, based on the limited evidence at certain time point, supplementing with post authorization monitoring and continued performance evidence to adjust the regulatory decisions as necessary.

475

The following mechanisms is a full-fledged regulatory set up. Depending on the local adoption of
reliance and recognition model across the life cycle of a product, some of the following steps can
be omitted.

479

480 6.1 Eligibility

Health authorities should set up certain eligibility criteria for assessment of which products will qualify
 for the emergency regulatory pathway. The following criteria is proposed as reference:

483 484

- The disease for which the product is intended for is serious or life threatening, or has severe impact on public health.
- There are urgent clinical needs due to lack of licensed products available in the market for
 the intended purpose, or the marketed products could not meet the requirements is terms of
 quality, performance, or scale-up capacity, etc.
- 489
 489 The known & potential benefits outweigh the known & potential risks based on the best available knowledge.

- The product is manufactured under a functional Quality Management System (QMS).
- 492
 493
 The applicant undertakes to complete the development of the product (validation and verification of the product).

In certain circumstances, respective authorities could consider special cases where the applicants
 may not meet the above requirements but due to the heightened risks or other reasons, these may
 still be considered and supported with justifications.


497


498 **6.2 Procedures**

As shown in Figure 3, the Emergency Regulatory Mechanism is activated post the Declarationof Emergency by the respective authority.

502 **Figure 3:** Process Map for Emergency Regulatory Mechanism

503





505 **6.2.1 Expert group**

Expert groups will be formed to consult on the evaluation of a specific product or group of products
 for the specific disease. It is recommended to have a multi-disciplinary expert group, including
 medical and clinical experts, R&D specialists, public health professionals, and others.

509

510 6.2.2 Pre-EUA submission meeting

511 It is recommended to set up pre-submission meeting mechanism to enable early conversations during 512 the product development phase. These meetings may be voluntary, but can be helpful in guiding

512 manufacturers to provide the relevant evidence needed for an emergency use authorization.

514

515 **6.2.3 EUA Submission**

516 It is recommended to allow special submission routes with more flexibility, including fast-route, 517 electronic submission, acceptance of electronic signature, acceptance of non-notarized or non-legalized 518 copy while requesting for later supplements when the notarization/legalization is logistically possible. 519 Regulatory authorities should also accommodate rolling submissions, in which manufacturers submit 520 evidence and Regulatory Authorities review it as completed.

- 521
 522 The Annex of this guideline provides the essential requirements for emergency regulatory
 523 authorization and documents (section A and B) provided for the EUA submission.
 - 1. Section A, B and C of this guideline provide a Table of Contents for the Submission Dossier of a General Medical Device, Software as a Medical Device and IVD Medical Devices.
- 527 2. Section D of this guideline provides the Quality Management System requirements
- 528
 3. Section E and F of this guideline provide basic Clinical Evidence requirements of a General Medical Device, Software as a Medical Device and IVD Medical Devices.
- 530 4. Section G of this guideline outlines Labelling requirements
- 531

524 525

526

532 6.2.4 Review/Audit/Inspection

Review and Audit could be optional if the reliance/recognition/reference authorization will beleveraged. In general, remote audit should be allowed.

535 It is recommended to temporarily postpone all domestic and foreign inspections, while only 536 conducting critical inspections when possible.

Remote inspections require a reliable Wi-Fi network, a stable internet connection, up-to-date remote video communication system, a mobile device enabled with video streaming function and connectivity to the internet (for virtual live tour), document scanner and document exchange platform, where possible. Platforms need to be cyber secure.

541

542 6.2.5 Emergency Authorization

- 543 The assessment timelines of an emergency authorization should be adapted to an emergency
- 544 context. It also should be communicated with the public via appropriate channels.
- 545

546 6.2.6 Post authorization monitoring

547

551

548 Once a product is granted emergency authorization, authorities should consider implementing post
549 authorization control measures to mitigate risk and address any product problems quickly, as below:
550 • Request for reports on safety surveillance or additional information as specified in the

- Request for reports on safety surveillance or additional information as specified in the emergency approval license;
- Efficacy/effectiveness/performance monitoring/safety;
- Quality complaints and other relevant data that may impact the validity of the listing status.
- 554 Regulatory Authorities should periodically review the appropriateness of an EUA. Once the
- 555 product is on the market, the review should include regular assessment based on additional
- information provided by the manufacturer as specified in the emergency authorisation decision
- If any quality/safety issues are identified post authorization and cannot be resolved to regulatory
 authority's satisfaction, the regulatory authority may revoke or modify the emergency authorization of
 the product.
- 561 Postmarket surveillance activities should where possible, comply with AHWP/WG4/F001:2015 -
- 562 Adverse Event Reporting Guidance for the Medical Device Manufacturer or its Authorized
- 563 Representative and AHWP/WG4/F001:2014 Adverse Event Reporting Timelines Guidance for
- 564 *Medical Device Manufacturer and its Authorised Representative* (AHWP/WG4/F001:2014)
- 565

566 **6.2.7** Changes

567

568 It is the applicant's responsibility to promptly inform authorities of all changes regarding intended use 569 formulation, manufacturing process, testing methods, specifications, facilities and any other aspects 570 that might result in a change of the safety and/or efficacy and/or performance of the product.

571

572 It is recommended to handle the changes in a prioritized and fast manner as these changes may happen 573 due to the evolving knowledge about the disease, or the evolvement of pathogen itself. It is also 574 recommended to leverage the reliance/recognition model for handling of changes, if it is the same 575 product and same change.

- 576
- For SaMD it is recommended to use predetermined change control plans to address anticipated futurechanges.
- 579 The manufacturer should where possible, comply with the GHWP guidances AHWP/WG2-
- 580 WG1-WG3/F001:2019 Categorisation of Changes to a registered Medical Device and
- 581 AHWP/WG1/F002:2016 Guidance for Minor Change Reporting.
- 582

583 **6.2.8 Duration**

- 584 In general, the emergency regulatory mechanism will remain in effect for the duration of the
- 585 Emergency Declaration issued by the Regulatory Authority. It is recommended to refer to the
- 586 global competent authority (i.e. WHO) decision in the case of global pandemic, due to the
- 587 potential risks of resurgence and pathogen mutation, etc.

588

589 **6.2.9 Conversion**

590 Once a medical device has been authorized under the Emergency Use Authorization mechanism, 591 the manufacturer of the device is expected to pursue regular marketing authorization. The EUA 592 ends upon the termination of the emergency situation and, unless regular marketing authorization 593 has been or is likely to be granted, the manufacturer should withdraw the device from the market 594 and recommend to discontinue use of the device. A transition period may be granted.

595

596 The Regulatory Authority should consider the post authorization data, including the Real World Data 597 (RWD) and associated Real World Evidence (RWE) as clinical evidence to assess if the requirements 598 of a normal license could be fulfilled. If it can be fulfilled, it is recommended to convert the emergency 599 authorization into full license in a simplified and prioritized manner.

- 600
- 601 The conversion can happen before or when the emergency declaration is terminated. Regulatory
- Authorities may consider reasonable transition periods to enable review of products seeking normal
- 603 licenses, and withdrawal of those for which manufacturers choose not to seek licenses. It is notable
- 604 that even after the emergency status is over, some of these products may still be critical components 605 for disease monitoring and diagnosis under the normal mode.
- 605 606

Annex: Essential requirements for emergency regulatory authorization of Medical Devices

609 A. Table of Content for Dossier for Medical Devices

- 610
- 611 An applicant for the authorization of importation or sale of an emergency use medical device or
- 612 software as medical device must contain sufficient information and material to enable the
- 613 Regulatory Authority to determine whether to issue the emergency use authorization.
- 614 GHWP recommends that the following information be submitted in any request for an 615 emergency regulatory authorization:
- 616 1. the risk class of the device;
- 617 2. the identifier of the device, including the identifier of any medical device that is part of a618 system
- 619 3. the name and address of the manufacturer as it appears on the device label;
- 4. the address where the device is manufactured, if different from the one referred to in paragraph (d);
- 622 5. description of the product's approval status (e.g. whether the product is approved in a
 623 foreign country for either the proposed use or another use; information on the use of the
 624 medical product by either a foreign country or an international organization (e.g., World
 625 Health Organization (WHO));
- 626 6. description of the product and its intended use
- 627 7. discussion of risks and benefits of the Medical Device
- 628 8. the known information in relation to the quality, safety and effectiveness of the device;
- 629 9. the Instructions for use for the device to be used safely and effectively;
- 630 10. an attestation by the applicant that documented procedures are in place in respect of
 631 distribution records, complaint handling, incident reporting and recalls; and
- 632 11. copy of the label of the device;
- 633 12. copy of the manufacturer's Quality Manufacturing System Certificate, evidence of Good
 634 Manufacturing Practices, or others.
- 635 636
- 637
- 638
- 639
- 640
- 641

642 **B. Table of Content for Dossier for IVD Medical Devices**

643

An applicant for the authorization of importation or sale of an emergency use IVD medical
 device must contain sufficient information and material to enable the Regulatory Authority to

646 determine whether to issue the emergency use authorization.

647 GHWP recommends that the following information be submitted in any request for an648 emergency regulatory authorization:

- 649 1. the risk class of the device;
- 650
 651
 651
 651
 652
 652
 651
 652
 652
 653
 654
 654
 655
 655
 655
 656
 657
 657
 657
 658
 659
 659
 650
 650
 650
 651
 651
 651
 652
 652
 653
 654
 654
 655
 655
 655
 656
 657
 657
 657
 658
 658
 659
 659
 650
 650
 650
 651
 651
 652
 652
 652
 653
 654
 654
 654
 655
 655
 655
 656
 657
 657
 657
 658
 658
 658
 659
 659
 659
 650
 650
 650
 650
 651
 651
 652
 652
 652
 652
 654
 655
 655
 655
 656
 657
 657
 657
 658
 658
 658
 659
 659
 659
 650
 650
 650
 650
 651
 651
 652
 652
 652
 654
 654
 655
 655
 656
 657
 657
 657
 658
 658
 658
 658
 658
 658
 658
 658
 658
 658
 658
 658
 658
 659
 659
 659
 659
 659
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
- 653 3. the name and address of the manufacturer as it appears on the device label;
- 4. the address where the device is manufactured, if different from the one referred to in paragraph (d);
- 656
 5. description of the product's approval status (e.g. whether the product is approved in a
 657
 658
 658
 659
 659
 5. description of the product's approval status (e.g. whether the product is approved in a
 659
 659
 650
 650
 650
 651
 652
 653
 654
 655
 655
 655
 656
 657
 657
 658
 659
 658
 659
 659
 650
 650
 650
 650
 650
 651
 652
 653
 654
 655
 655
 655
 656
 657
 657
 657
 658
 658
 658
 659
 658
 659
 659
 659
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650
 650<
- 6. description of the product and its intended use (e.g., identification of the serious or life61 threatening disease or condition for which the product may be effective; where, when,
 and how the product is anticipated to be used; and/or the population(s) for which the
 product may be used);
- 664 7. discussion of risks and benefits of the IVD Medical Device
- 8. the known information in relation to the quality, safety and effectiveness of the device;
- 666 9. the Instructions for use for the device to be used safely and effectively;
- an attestation by the applicant that documented procedures are in place in respect of
 distribution records, complaint handling, incident reporting and recalls; and
- 669 11. copy of the label of the device;
- 670 12. copy of the manufacturer's Quality Manufacturing System Certificate, evidence of Good
 671 Manufacturing Practices, or others.

681

683 C. Table of Content for Dossier for Software as Medical Device

684

An applicant for the authorization of importation or sale of an emergency use medical device or
 software as medical device must contain sufficient information and material to enable the
 Regulatory Authority to determine whether to issue the emergency use authorization.

- 688 GHWP recommends that the following information be submitted in any request for an 689 emergency regulatory authorization:
- 690 1. the risk class of the device, and / or Level of Concern if known;
- 691
 692
 693
 2. the identifier of the device, including the identifier that may work alone or together with any medical device as part of a system, test kit, medical device group, medical device family or medical device group family, where applicable;
- 694
 695
 3. the name and address of the manufacturer as it appears on the device label or software interface;
- 696
 697
 4. the address where the device is manufactured, if different from the one referred to in paragraph (3);
- 698
 5. description of the product's approval status, including EUA approval status in other
 699
 700
 701
 5. description of the product's approval status, including EUA approval status in other
 699
 700
 701
 701
 701
 702
 703
 704
 705
 706
 706
 707
 708
 708
 709
 709
 709
 700
 700
 700
 700
 700
 701
 701
 701
 701
 701
 701
 702
 703
 704
 704
 705
 705
 706
 706
 707
 708
 708
 709
 709
 709
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 700
 <
- 702 6. description of the product and its intended use;
- 703 7. discussion of risks and benefits of the SaMD;
- 8. list of unresolved anomalies (for Moderate and Major Level of Concern SaMD, if available);
- 9. the known information in relation to the quality, safety and effectiveness of the device;
- the Instructions for use (or operator manual) for the device to be used safely and
 effectively;
 - 11. an attestation by the applicant that documented procedures are in place in respect of distribution records, complaint handling, incident reporting and recalls; and
- 711 12. copy of the label of the device (applicable only if physical optical disc is used for distribution);
- copy of the manufacturer's Quality Manufacturing System Certificate, evidence of
 Good Manufacturing Practices, or others where applicable.
- 715

709

- 716
- 717
- 718
- 719
- 720 721
- 722
- 723

724 **D. Quality Management System Documents**

725

A review of the manufacturer's quality management system (QMS) documentation and specific
 manufacturing documents is the first step in the process.

- The quality management standard *ISO 13485 Medical devices Quality management systems— Requirements for regulatory purposes* should be considered a benchmark in quality management
 for manufacturers of Medical Devices by regulatory authorities throughout the world.
- 732

733 Manufacturers will be required to share information to demonstrate that the general MD/IVD

medical device/SaMD for emergency use are of consistent quality and effectiveness. This can be

- demonstrated by either providing a copy of the manufacturer's Quality Management System
- certificate to ISO 13485:2016, or by submitting evidence of Good Manufacturing Practices andits proper implementation.
- 738 In the absence of a valid ISO 13485:2016 certificate, information supporting the following
- riteria, as a minimum, should be included in an application for a general MD/IVD medical
- 740 device/SaMD:
- 741 **Design** A documented process for controlling design and development.

Planning - Evidence of adequate quality planning, such as final approved specification for the
 product and all components, including labelling, Instructions for Use (IFU), packaging

- 744 **Purchasing controls** Evidence of adequate purchasing controls
- 745 **Manufacturing/production** Documented procedures and work instructions
- 746 Corrective actions and post-market activities Documented procedures and work instructions
 747 (as appropriate)
- 748
- 749
- 750
- 751

752 E. Clinical Evidence Requirements – Medical Devices and Software as Medical Devices

While the ultimate objective is to fully verify the clinical safety and efficacy of the Medical Device, the pandemic crisis, the urgent need for patient treatment, and the possible lack of supplies might make it difficult to fully evaluate the clinical safety and efficacy that are normally required to gain the product approval under non-emergency circumstances in most jurisdictions. A limited preliminary clinical evidence may be acceptable. The manufacturer should follow a risk based approach and determine the depth of verification needed. Various scientific evidence can be considered to make an overall risk-benefit determination and such evidence may include but not limited to: Results of domestic and foreign clinical trials • in vivo safety and efficacy data from animal models • in vitro efficacy data • The Regulatory Authorities should consider that not all studies are completed when submitting in an EUA submission. When studies are still in progress or plans to commence such studies are in place, the manufacturer should provide the study protocol and an update of progress or the study protocol and plan along with anticipated dates of completion. If more clinical data become available at a later time, the manufacturer should submit these data to the Regulatory Authority. Additionally the Regulatory Authorities might consider establishing some technology-specific guidance documents to support applicants regarding clinical evidence requirements.

796 **F.** Clinical Evidence Requirements – IVD Medical Devices

797

While the ultimate objective is to fully verify the method performance of the IVD Medical
Device, the pandemic crisis, the urgent need for patient testing, and the possible lack of reagents

- and supplies might make it difficult to fully evaluate the performance as outlined in
- AHWP/WG5/F003:2015 Clinical Evidence for IVD Medical Device Key Definitions and
 Concepts,
- AHWP/WG5/F004:2015 Clinical Evidence for IVD Scientific Validity Determination and
 Performance Evaluation
- AHWP Guidance on Clinical Evidence for IVD Medical Devices Clinical Performance
 Studies for In Vitro Diagnostic Medical Devices
- A limited preliminary clinical evidence may be acceptable. The manufacturer should follow a
 risk based approach and determine the depth of verification needed based on the available
 scientific knowledge at the time of EUA.

810

812

819

821

824

825

- 811 Analytical performance studies might include but not limited to:
 - Stability of specimen(s)
- Validation of specimens matrix equivalence studies "Validation of specimens evaluation of different matrices" Reason is Matrices may not be equivalent due to
 biological factors, and a matrix with inferior performance may still be useful in
 situations of scarcity.
- Precision (repeatability and reproducibility)
- Analytical sensitivity
 - Analytical specificity (interfering substances and cross reactivity)
- Cut-off value
 - Validation of assay procedure:
- Stability studies
- 823 Clinical performance studies might include but not limited to:
 - Clinical / diagnostic sensitivity
 - Clinical/ diagnostic specificity
 - Recommended comparator method/ assigning clinical truth to specimens
- 826 827

The Regulatory Authorities should consider that not all studies are completed when submitting in an EUA submission. When studies are still in progress or plans to commence such studies are in place, the manufacturer should provide the study protocol and an update of progress or the study protocol and plan along with anticipated dates of completion. If more clinical data become

available at a later time, the manufacturer should submit these data to the Regulatory Authority.

- 833
- The Regulatory Authorities should consider to accept contrived specimens given that clinical
- specimens will not always be available in the volumes required, especially when countries are
- 836 experiencing fluctuating numbers of cases.
- 837

838 839 840 841 842	The Regulatory Authorities should consider to accept and leverage the clinical evidence (from other countries or regions) rather than asking for local clinical studies. Local studies should only be required if there is a lack of sufficient scientific evidence. Additionally the Regulatory Authorities might consider establishing some technology-specific guidance documents to support applicants regarding clinical evidence requirements.
843	
844	
845	
846	
847	
848	
849	
850	
851	
852	
853	
854	
855	
856	
857	
858	
859	
860	
861	
862	
863	
864	
865	
866	
867	

868 G. Labelling

869

- 870 The labelling should clearly display information regarding its status for emergency use only
- 871 (EUA).

- 873 The information contained within the IFU may be electronically provided as an acceptable
- alternative to be compliant with regulatory requirements. eIFU should, where possible, comply
- 875 with the GHWP guidance "Principles of Regulatory Requirements for Electronic Instructions for
- 876 Use (eIFU), AHWP/WG1-WG2-WG3/F002:2019 "and or local regulations.